| 2023-12-05 | +125.7% | legal | SEC EDGAR | SKYE 8-K: 1.01, 1.02 (SEC Filing) |
| 2025-10-06 | -65.0% | news | Seeking Alpha | Skye Bioscience, Inc. (SKYE) CBeyond Phase 2a Clinical Trial Topline Data Conference Call Transcript |
| 2025-10-06 | -65.0% | news | Seeking Alpha | Skye Bioscience, Inc. (SKYE) Special Call - Slideshow |
| 2025-10-06 | -65.0% | news | Seeking Alpha | Skye plummets 60% on mid-stage data for nimacimab for weight loss |
| 2025-10-06 | -65.0% | news | Investing.com | Skye Bioscience stock plummets after failed weight loss drug trial - Investing.com |
| 2025-10-06 | -65.0% | news | Stocktwits | Why Did Skye Bioscience Stock Plummet A Whopping 60% Today? - Stocktwits |
| 2025-10-06 | -65.0% | analyst | Investing.com | Citizens lowers Skye Bioscience stock price target to $4 from $16, maintains Market Outperform rating - Investing.com |
| 2025-10-06 | -65.0% | news | BioPharma Dive | Skye shares crash as obesity drug falls short in key study - BioPharma Dive |
| 2025-10-06 | -65.0% | news | TipRanks | Skye Bioscience Reveals Phase 2a Study Results - TipRanks |
| 2025-10-06 | -65.0% | news | Benzinga | Spruce Biosciences Stock Is Soaring Today: Here's Why - Spruce Biosciences (NASDAQ:SPRB) - Benzinga |
| 2025-10-06 | -65.0% | news | Benzinga | US Stocks Mixed; Dow Falls 100 Points - Advanced Micro Devices (NASDAQ:AMD), Dragonfly Energy Holdings (N - Benzinga |
| 2024-04-10 | +38.6% | news | Yahoo Finance | Skye Bioscience Uplists to The Nasdaq Global Market - Yahoo Finance |
| 2024-01-29 | +34.3% | legal | SEC EDGAR | SKYE 8-K: 1.01, 3.02, 7.01, 8.01 (SEC Filing) |
| 2025-06-22 | +31.9% | analyst | Yahoo Finance | Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks - Yahoo Finance |
| 2023-08-21 | -31.6% | legal | SEC EDGAR | SKYE 8-K: 1.01, 2.01, 2.03, 3.02, 5.02, 7.01 (SEC Filing) |
| 2024-08-23 | +29.1% | news | GlobeNewswire | Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire |
| 2024-07-03 | -28.3% | legal | SEC EDGAR | SKYE 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-06-24 | +27.4% | news | Investing.com | Skye Bioscience’s SWOT analysis: nimacimab’s potential shakes up obesity stock landscape - Investing.com |
| 2024-03-13 | +23.8% | legal | SEC EDGAR | SKYE 8-K: 1.01, 3.02 (SEC Filing) |
| 2025-03-21 | +22.8% | news | Seeking Alpha | Skye Bioscience accelerates nimacimab clinical trial timeline with early enrollment and extended treatment period |
| 2025-03-21 | +22.8% | earnings | Seeking Alpha | Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript |
| 2022-11-11 | -21.8% | legal | The Canadian Securities Exchange (CSE) | 2022-1118 - Delist - Emerald Health Therapeutics, Inc. (EMH) - The Canadian Securities Exchange (CSE) |
| 2023-09-07 | -21.1% | news | Yahoo Finance | Skye Bioscience Reverse Stock Split to Be Effective on September 8th - Yahoo Finance |
| 2025-03-19 | -18.3% | earnings | Seeking Alpha | Skye Bioscience Q4 2024 Earnings Preview |
| 2022-05-23 | -14.4% | legal | SEC EDGAR | SKYE 8-K: 1.01, 5.02 (SEC Filing) |
| 2023-01-06 | -14.0% | legal | SEC EDGAR | SKYE 8-K: 1.01, 5.02 (SEC Filing) |
| 2025-04-16 | -14.0% | news | Seeking Alpha | A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value |
| 2025-04-16 | -14.0% | news | Seeking Alpha | A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha |
| 2025-10-01 | +13.8% | analyst | Seeking Alpha | Skye Bioscience: Promising Nimacimab Data Supports Buy Rating |
| 2025-10-01 | +13.8% | analyst | Seeking Alpha | Skye Bioscience: Promising Nimacimab Data Supports Buy Rating (NASDAQ:SKYE) - Seeking Alpha |
| 2026-01-05 | +13.8% | news | Investing.com | Skye Bioscience stock jumps after Halozyme collaboration for obesity drug - Investing.com |
| 2026-01-05 | +13.8% | news | Stock Titan | Biotechs team up to test higher-dose obesity shots in mid-2026 trial - Stock Titan |
| 2023-03-27 | -13.6% | legal | SEC EDGAR | SKYE 8-K: 5.02 and (SEC Filing) |
| 2022-12-19 | -13.6% | legal | SEC EDGAR | SKYE 8-K: 1.01 and (SEC Filing) |
| 2025-05-22 | -13.4% | news | Intellectia AI | SKYE Forecast — Price Prediction for 2026. Should I Buy SKYE? - Intellectia AI |
| 2025-03-20 | +13.1% | earnings | Seeking Alpha | Skye Bioscience GAAP EPS of -$0.24 beats by $0.04 |
| 2025-03-20 | +13.1% | legal | SEC EDGAR | SKYE 8-K: 2.02 and (SEC Filing) |
| 2026-01-08 | -12.4% | legal | openPR.com | Lawsuit Alert: Investors who lost money with shares of Skye - openPR.com |
| 2025-05-09 | +11.4% | earnings | Seeking Alpha | Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript |
| 2025-05-09 | +11.4% | earnings | Seeking Alpha | Skye Bioscience, Inc. 2025 Q1 - Results - Earnings Call Presentation |
| 2026-02-02 | -10.3% | news | GlobeNewswire | Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide |
| 2026-02-02 | -10.3% | legal | SEC EDGAR | SKYE 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-02-02 | -10.3% | earnings | Stock Titan | Obesity drug combo keeps weight off: Skye study shows 22.3% loss - Stock Titan |
| 2026-02-02 | -10.3% | news | Benzinga | Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year - Benzinga |
| 2026-02-02 | -10.3% | news | TipRanks | Skye Bioscience Reports Promising Phase 2a Obesity Data - TipRanks |
| 2026-02-02 | -10.3% | news | GuruFocus | Skye Bioscience (SKYE) Reports Promising Results from CBeyond Ex - GuruFocus |
| 2026-03-09 | +10.3% | earnings | Seeking Alpha | Skye Bioscience Q4 2025 Earnings Preview |
| 2025-08-07 | -10.2% | earnings | Seeking Alpha | Skye Bioscience GAAP EPS of -$0.44 misses by $0.13 |
| 2025-08-07 | -10.2% | legal | SEC EDGAR | SKYE 8-K: 2.02 and (SEC Filing) |
| 2025-08-07 | -10.2% | legal | GlobeNewswire | Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update - GlobeNewswire |
| 2025-12-23 | -10.2% | legal | SEC EDGAR | SKYE 8-K: 1.01 (SEC Filing) |
| 2025-05-11 | +10.0% | news | Intellectia AI | SKYE Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2025-09-05 | +9.9% | news | Seeking Alpha | Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript |
| 2026-03-11 | -9.9% | news | Seeking Alpha | Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy |
| 2026-03-11 | -9.9% | earnings | Seeking Alpha | Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript |
| 2026-03-11 | -9.9% | analyst | Investing.com | Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral - Investing.com |
| 2026-03-11 | -9.9% | analyst | Investing.com | Citizens reiterates Skye Bioscience stock rating on weight loss data - Investing.com |
| 2025-10-07 | -9.7% | news | Yahoo Finance | Why Skye Bioscience (SKYE) Is Down 51.0% After Releasing Phase 2a Nimacimab Trial Results and What's Next - Yahoo Finance |
| 2025-10-07 | -9.7% | earnings | TradingView | SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal - TradingView |
| 2026-02-04 | -9.6% | news | simplywall.st | Here's Why Skye Bioscience (NASDAQ:SKYE) Must Use Its Cash Wisely - simplywall.st |
| 2024-03-29 | -9.2% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for Skye Bioscience (SKYE) - Zacks Investment Research |
| 2025-02-10 | -8.7% | news | Seeking Alpha | Smaller biotechs see new mechanisms of action as future of obesity treatments |
| 2026-04-22 | +8.3% | analyst | Cổng thông tin điện tử tỉnh Lào Cai | Skye Bioscience (SKYE) Stock: Continuation Signals (At Highs) 2026-04-22 - Top Analyst Picks - Cổng thông tin điện tử tỉnh Lào Cai |
| 2021-09-28 | -8.3% | legal | SEC EDGAR | SKYE 8-K: 1.01, 8.01 (SEC Filing) |
| 2026-02-17 | +7.5% | earnings | PR Newswire | HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE |
| 2025-11-24 | +7.4% | executive | Scott Coop | Skye Bioscience to Participate in Upcoming Investment Conferences - Scott Coop |
| 2023-02-23 | +7.2% | legal | SEC EDGAR | SKYE 8-K: 1.01, 1.02, 3.02 (SEC Filing) |
| 2024-03-04 | +7.2% | legal | SEC EDGAR | SKYE 8-K: 5.02, 8.01 (SEC Filing) |
| 2021-07-22 | -7.1% | legal | SEC EDGAR | SKYE 8-K: 1.01, 3.02 (SEC Filing) |
| 2024-06-10 | -7.0% | legal | SEC EDGAR | SKYE 8-K: 8.01 and (SEC Filing) |
| 2024-06-10 | -7.0% | news | Investor's Business Daily | Small Biotech Crushed On Obesity Switch After Glaucoma Flop - Investor's Business Daily |
| 2025-08-06 | -7.0% | earnings | Seeking Alpha | Skye Bioscience Q2 2025 Earnings Preview |
| 2025-08-05 | +6.9% | news | Yahoo Finance | We Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth Carefully - Yahoo Finance |
| 2026-04-02 | +6.8% | news | GlobeNewswire | Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development |
| 2026-04-02 | +6.8% | news | Stock Titan | Director at Skye Bioscience (NASDAQ: SKYE) receives 75,000-share stock option grant - Stock Titan |
| 2026-04-02 | +6.8% | news | Stock Titan | Skye Bioscience (SKYE) director receives 75,000 stock options at $0.615 strike - Stock Titan |
| 2026-04-02 | +6.8% | news | Stock Titan | Skye tests higher nimacimab doses ahead of Phase 2b obesity combo - Stock Titan |
| 2026-04-02 | +6.8% | news | Stock Titan | Skye Bioscience (SKYE) director Paul A. Grayson receives 75,000 stock options - Stock Titan |
| 2026-04-02 | +6.8% | news | Stock Titan | Skye Bioscience (SKYE) director awarded 75,000 stock options at $0.6150 - Stock Titan |
| 2026-04-02 | +6.8% | executive | Stock Titan | Skye Bioscience (SKYE) reprices CEO stock options to $0.615 strike - Stock Titan |
| 2026-04-02 | +6.8% | news | Stock Titan | Director at Skye Bioscience (SKYE) awarded 75,000 stock options at $0.615 - Stock Titan |
| 2026-04-02 | +6.8% | news | GlobeNewswire | Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development - GlobeNewswire |
| 2025-11-11 | +6.8% | earnings | Seeking Alpha | Skye Bioscience outlines higher dose strategy for nimasimab in Q4 data-driven development |
| 2025-11-11 | +6.8% | earnings | Seeking Alpha | Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript |
| 2024-07-01 | -6.5% | news | ChartMill | SKYE Technical Analysis | Trend, Signals & Chart Patterns | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill |
| 2021-10-15 | -6.5% | legal | SEC EDGAR | SKYE 8-K: 1.01, 8.01 (SEC Filing) |
| 2026-03-12 | -6.4% | earnings | GuruFocus.com | Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pioneering Advances in Obesity ... |
| 2025-11-10 | -6.4% | earnings | Seeking Alpha | Skye Bioscience GAAP EPS of -$0.32 misses by $0.01 |
| 2025-11-10 | -6.4% | legal | SEC EDGAR | SKYE 8-K: 2.02 and (SEC Filing) |
| 2025-11-10 | -6.4% | news | Yahoo Finance | Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update - Yahoo Finance |
| 2025-12-24 | -6.2% | news | Benzinga | Why Multi Ways Holdings Shares Are Trading Higher By Around 60%; Here Are 20 Stocks Moving Premarket - Benzinga |
| 2023-02-16 | -6.1% | legal | SEC EDGAR | SKYE 8-K: 5.02, 8.01 (SEC Filing) |
| 2025-02-26 | -5.7% | legal | SEC EDGAR | SKYE 8-K: 5.02 and (SEC Filing) |
| 2021-12-20 | -5.7% | legal | SEC EDGAR | SKYE 8-K: 5.02, 8.01 (SEC Filing) |
| 2022-11-23 | -5.6% | legal | SEC EDGAR | SKYE 8-K: 1.01, 3.03 (SEC Filing) |
| 2023-09-01 | -5.3% | legal | SEC EDGAR | SKYE 8-K: 5.02 (SEC Filing) |
| 2023-10-03 | -5.2% | legal | SEC EDGAR | SKYE 8-K: 5.02, 8.01 (SEC Filing) |
| 2026-02-03 | -5.1% | analyst | Investing.com | H.C. Wainwright reiterates Buy rating on Skye Bioscience stock at $20 - Investing.com |
| 2024-11-07 | +5.1% | legal | SEC EDGAR | SKYE 8-K: 2.02 and (SEC Filing) |
| 2022-06-17 | -5.1% | legal | SEC EDGAR | SKYE 8-K: 1.01, 4.01, 5.02 (SEC Filing) |
| 2024-04-12 | +5.1% | news | CNN | SKYE Stock Quote Price and Forecast - CNN |
| 2024-04-12 | +5.1% | earnings | MarketBeat | Top Skye Bioscience (SKYE) Competitors 2026 - MarketBeat |
| 2024-04-12 | +5.1% | earnings | MarketBeat | Skye Bioscience (SKYE) Earnings Date and Reports 2026 - MarketBeat |
| 2024-04-12 | +5.1% | earnings | MarketBeat | Skye Bioscience (SKYE) Stock Chart and Price History 2026 - MarketBeat |
| 2025-05-23 | +4.9% | news | Zacks Investment Research | Should I buy Skye Bioscience (SKYE) - Zacks Investment Research |
| 2025-05-23 | +4.9% | news | Yahoo Finance | 3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies - Yahoo Finance |
| 2025-07-07 | -4.8% | news | Seeking Alpha | Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing (NASDAQ:SKYE) - Seeking Alpha |
| 2023-01-27 | +4.6% | legal | SEC EDGAR | SKYE 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-07-08 | -4.4% | news | Seeking Alpha | Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing |
| 2025-10-15 | -4.4% | legal | Claim Depot | Skye Bioscience, Inc. Securities Lawsuit Investigation - Claim Depot |
| 2024-02-12 | -4.1% | legal | SEC EDGAR | SKYE 8-K: 8.01 and (SEC Filing) |
| 2023-02-15 | -4.1% | legal | SEC EDGAR | SKYE 8-K: 1.01, 2.01, 8.01 (SEC Filing) |
| 2025-08-15 | +3.9% | news | Seeking Alpha | Skye initiated at overweight at Evercore on obesity asset nimacimab |
| 2024-10-09 | -3.9% | earnings | MarketBeat | Don’t Sleep on Skye Bioscience—This Weight Loss Drug Could Soar - MarketBeat |
| 2021-07-26 | +3.7% | legal | SEC EDGAR | SKYE 8-K: 5.02, 8.01 (SEC Filing) |
| 2026-04-07 | -3.6% | news | GlobeNewswire | Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit |
| 2026-04-07 | -3.6% | news | GlobeNewswire | Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit - GlobeNewswire |
| 2024-10-24 | -3.5% | legal | SEC EDGAR | SKYE 8-K: 5.02, 5.07 (SEC Filing) |
| 2024-09-04 | +3.3% | legal | SEC EDGAR | SKYE 8-K: 5.02, 7.01 (SEC Filing) |
| 2024-09-04 | +3.3% | news | Seeking Alpha | Skye: Moving Weight Loss Drugs To The Next Level - Seeking Alpha |
| 2021-09-15 | -3.1% | legal | SEC EDGAR | SKYE 8-K: 5.02, 8.01 (SEC Filing) |
| 2026-02-20 | +2.9% | legal | SEC EDGAR | SKYE 8-K: 5.02 (SEC Filing) |
| 2025-02-22 | -2.6% | news | Yahoo Finance | We're Hopeful That Skye Bioscience (NASDAQ:SKYE) Will Use Its Cash Wisely - Yahoo Finance |
| 2022-07-21 | +2.6% | legal | SEC EDGAR | SKYE 8-K: 1.01 and (SEC Filing) |
| 2025-09-10 | +2.3% | news | Seeking Alpha | Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript |
| 2024-04-13 | +1.9% | analyst | TradingView | SKYE Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-04-04 | +1.8% | legal | Stock Titan | SKYE SEC Filings - Skye Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2026-04-03 | +1.8% | legal | SEC EDGAR | SKYE 8-K: 5.02 and (SEC Filing) |
| 2026-04-03 | +1.8% | executive | Stock Titan | Skye Bioscience (SKYE) reprices 2.42M options and taps John Sharp as CFO - Stock Titan |
| 2025-08-08 | -1.7% | earnings | Seeking Alpha | Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform |
| 2025-08-08 | -1.7% | earnings | Seeking Alpha | Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript |
| 2026-03-19 | -1.6% | news | Stock Titan | Nasdaq warns Skye Bioscience (SKYE) after shares stay under $1 minimum - Stock Titan |
| 2026-03-19 | -1.6% | news | Investing.com | Skye Bioscience receives Nasdaq notice for minimum bid price deficiency - Investing.com |
| 2026-03-19 | -1.6% | news | TipRanks | Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice - TipRanks |
| 2022-10-19 | +1.5% | legal | SEC EDGAR | SKYE 8-K: 1.01, 2.03 (SEC Filing) |
| 2025-06-19 | +1.5% | news | Seeking Alpha | Skye confirms phase 2 data on nimacimab for obesity expected later this year |
| 2024-04-11 | +1.4% | news | TradingView | SKYE Stock Price and Chart — NASDAQ:SKYE - TradingView |
| 2024-04-11 | +1.4% | news | TradingView | Technical Analysis of Skye Bioscience, Inc. (NASDAQ:SKYE) - TradingView |
| 2021-10-06 | -1.3% | legal | SEC EDGAR | SKYE 8-K: 5.02, 8.01 (SEC Filing) |
| 2025-05-08 | -1.1% | earnings | Seeking Alpha | Skye Bioscience GAAP EPS of -$0.28 beats by $0.01 |
| 2025-05-08 | -1.1% | legal | SEC EDGAR | SKYE 8-K: 2.02 and (SEC Filing) |
| 2024-10-29 | -1.0% | legal | SEC EDGAR | SKYE 8-K: 5.02, 8.01 (SEC Filing) |
| 2024-10-29 | -1.0% | executive | Investing.com Canada | Skye Bioscience appoints new chairman to boost governance By Investing.com - Investing.com Canada |
| 2026-03-05 | -1.0% | news | GlobeNewswire | Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 |
| 2026-03-05 | -1.0% | news | Stock Titan | Clinical-stage obesity biotech Skye sets March 10 results call - Stock Titan |
| 2026-03-05 | -1.0% | news | GlobeNewswire | Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026 - GlobeNewswire |
| 2025-05-29 | -0.8% | news | CoinCodex | Skye Bioscience, Inc. (SKYE) Stock Forecast & Price Prediction 2026–2030 - CoinCodex |
| 2024-05-11 | +0.8% | earnings | MarketBeat | Skye Bioscience (SKYE) Stock Forecast and Price Target 2026 - MarketBeat |
| 2026-04-06 | +0.6% | legal | SEC EDGAR | SKYE 8-K: 5.02 (SEC Filing) |
| 2026-04-06 | +0.6% | news | Stock Titan | Skye Bioscience (SKYE) seeks to triple authorized shares; nimacimab posts 22.3% weight loss signal - Stock Titan |
| 2026-04-06 | +0.6% | news | Stock Titan | Skye Bioscience (SKYE) fixes share count for repriced stock options - Stock Titan |
| 2026-03-18 | -0.6% | earnings | MarketBeat | Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference |
| 2026-01-29 | +0.5% | news | GlobeNewswire | Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference |
| 2025-12-02 | +0.3% | legal | PR Newswire | SKYE Class Action Reminder: Skye Bioscience, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit - PR Newswire |
| 2022-05-12 | +0.2% | legal | SEC EDGAR | SKYE 8-K: 1.01, 3.02, 5.02, 8.01 (SEC Filing) |
| 2022-05-12 | +0.2% | M&A | Cannabis Equipment News | Skye Bioscience Acquiring Emerald Health Therapeutics - Cannabis Equipment News |
| 2024-05-15 | -0.2% | news | ChartMill | SKYE Stock Price, Quote & Chart | SKYE BIOSCIENCE INC (NASDAQ:SKYE) - ChartMill |
| 2026-03-10 | -0.1% | news | GlobeNewswire | Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-03-10 | -0.1% | earnings | Seeking Alpha | Skye Bioscience, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-03-10 | -0.1% | earnings | Seeking Alpha | Skye Bioscience GAAP EPS of -$0.36 misses by $0.06 |
| 2026-03-10 | -0.1% | legal | SEC EDGAR | SKYE 8-K: 2.02 (SEC Filing) |
| 2026-03-10 | -0.1% | news | GlobeNewswire | Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire |
| 2026-03-10 | -0.1% | earnings | MarketBeat | Skye Bioscience Q4 2025 Earnings Call Transcript - MarketBeat |
| 2026-03-10 | -0.1% | news | ChartMill | Get insights into the top gainers and losers of Tuesday's after-hours session. - ChartMill |
| 2026-01-12 | +0.0% | news | Yahoo Finance | Companies Like Skye Bioscience (NASDAQ:SKYE) Could Be Quite Risky - Yahoo Finance |
| 2026-01-12 | +0.0% | news | Yahoo Finance | Skye Provides 2026 Corporate Outlook - Yahoo Finance |
| 2026-01-12 | +0.0% | news | GlobeNewswire | SKYE BIOSCIENCE CLASS ACTION REMINDER: Bragar Eagel & - GlobeNewswire |